Cell analysis solutions company Cytek Biosciences ( NASDAQ: CTKB ) said on Thursday that the board has approved an up to $50M share repurchase program. The repurchase program is set to continue until December 31. Any repurchases will be made in the open market and/or in privately negotiated transactions, and may be made from time to time or in one or more larger repurchases.
Source: Press Release More on Cytek Biosciences Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Call Transcript Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader Seeking Alpha’s Quant Rating on Cytek Biosciences Historical earnings data for Cytek Biosciences Financial information for Cytek Biosciences.
